“The increasing number of veterans with posttraumatic stress disorder (PTSD) raises the risk of domestic violence and its consequences on families and children in communities across the United States,” says Monica Matthieu, Ph.D., an expert on veteran mental health and an assistant professor of social work at Washington University in St. Louis. “Treatments for domestic violence are very different than those for PTSD.
Domestic Violence A Growing Problem For Veterans
Published in November 8th, 2008
Posted by Alcohol / Addiction / Illegal Drugs News From Medical News Today in Addictions, Alcohol Abuse, Drugs and Food Information, Health Information, Illegal Drugs, Safety Information
Comments Off
New silver coated anti-microbial barrier dressing receives Canadian approval
Published in November 8th, 2008
Comments Off
NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, and the Advanced Wound Management division of Smith & Nephew plc announced today that Health Canada granted marketing approval for Acticoat Flex barrier dressing for wounds that require up to seven days of sustained antimicrobial activity.
Spherix starts patient recruitment in India for phase 3 diabetes trial
Published in November 8th, 2008
Comments Off
Spherix Incorporated reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose, has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial.
Response Genetics, Inc. Reports Third Quarter and Year-to-Date 2008 Financial Results
Published in November 8th, 2008
Comments Off
Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and commercialization of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and nine months ended September 30, 2008.
EMD Serono Launches Landmark Patient Registry for Egg Freezing
Published in November 8th, 2008
Comments Off
EMD Serono, Inc., an affiliate of Merck KGaA of Darmstadt, Germany, announced the launch of the Human Oocyte Preservation Experience (HOPE) Registry surrounding next week’s 64th Annual Meeting of the American Society for Reproductive Medicine (ASRM).
Redpoint Bio to Present at Rodman & Renshaw Annual Global Investment Conference
Published in November 8th, 2008
Comments Off
Redpoint Bio Corporation (OTCBB: RPBC), a company leveraging recent discoveries in the molecular biology of taste to discover and develop novel taste modulators for the food, beverage and pharmaceutical industries, today announced that Dr. Ray Salemme, Chief Executive Officer of Redpoint Bio, will present a corporate update at the Rodman & Renshaw Annual Global Investment Conference in New York, NY on Wednesday, November 12, 2008 at 11:35 A.M. Eastern Time.
Patient Recruitment Begins in India for Phase 3 Diabetes Trial
Published in November 8th, 2008
Comments Off
Spherix Incorporated ( NASDAQ:SPEX ) reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose(R), has begun in India. Expectations for India are to provide more than 300 patients spread across 35 sites for the pivotal Phase 3 trial.
New Acticoat(TM) Silver Coated Anti-microbial Barrier Dressing Receives Regulatory Approval from Health Canada
Published in November 8th, 2008
Comments Off
NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, and the Advanced Wound Management division of Smith & Nephew plc announced today that Health Canada granted marketing approval for Acticoat(TM) Flex barrier dressing for wounds that require up to seven days of sustained antimicrobial activity.
Acologix AC-200 Demonstrates Positive Effect on Bone in Preclinical Model of Chronic Kidney Disease
Published in November 8th, 2008
Comments Off
Acologix, Inc., a privately held biopharmaceutical company, will present data indicating that its therapeutic product candidate AC-200 improved bone architecture in a rat model of chronic kidney disease.
Molecular Insight Pharmaceuticals, Inc. To Present Results from a Prospective Analysis of Zemiva(TM) Phase 2b Data at the 2008 Scientific Sessions of the American Heart Association
Published in November 8th, 2008
Comments Off
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it will present results from a prospective analysis of Phase 2b data (BP-21) for its lead molecular imaging radiopharmaceutical candidate, Zemiva, as a poster at the 2008 Scientific Sessions of the American Heart Association in New Orleans, La.